Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
January 15 2025 - 12:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of January 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Emma Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2025
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.4950
|
898
|
|
|
|
£13.4950
|
1,492
|
|
|
|
£13.4950
|
1,686
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
4,076
£13.4950
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr Hal Barron
|
|
b)
|
Position/status
|
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 9 January 2025 on ADSs held in
the Company's Deferred Annual Bonus Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$33.7500
|
495
|
|
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Julie Brown
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2025
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.4950
|
643
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Diana Conrad
|
|
b)
|
Position/status
|
Chief People Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2025
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.4950
|
141
|
|
|
|
£13.4950
|
272
|
|
|
|
£13.4950
|
425
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
838
£13.4950
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
James Ford
|
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2025
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.4950
|
174
|
|
|
|
£13.4950
|
264
|
|
|
|
£13.4950
|
430
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
868
£13.4950
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Sally Jackson
|
|
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2025
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.4950
|
81
|
|
|
|
£13.4950
|
164
|
|
|
|
£13.4950
|
267
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
512
£13.4950
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Luke Miels
|
|
b)
|
Position/status
|
Chief Commercial Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2025
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.4950
|
295
|
|
|
|
£13.4950
|
801
|
|
|
|
£13.4950
|
636
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
1,732
£13.4950
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Shobie
Ramakrishnan
|
|
b)
|
Position/status
|
Chief
Digital and Technology Officer
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in ADSs following the re-investment of
dividends paid to shareholders on 9 January 2025 on ADSs held in
the Company's Deferred Annual Bonus Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$33.7500
|
130
|
|
|
|
$33.7500
|
203
|
|
|
|
$33.7500
|
30
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume
Price
|
363
$33.7500
|
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
David Redfern
|
|
b)
|
Position/status
|
President, Corporate Development
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2025
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.4950
|
368
|
|
|
|
£13.4950
|
196
|
|
|
|
£13.4950
|
510
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
1,074
£13.4950
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Regis Simard
|
|
b)
|
Position/status
|
President, Global Supply Chain
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2025
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.4950
|
178
|
|
|
|
£13.4950
|
295
|
|
|
|
£13.4950
|
614
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
1,087
£13.4950
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Philip Thomson
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2025
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.4950
|
123
|
|
|
|
£13.4950
|
193
|
|
|
|
£13.4950
|
343
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
659
£13.4950
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
|
a)
|
Name
|
Deborah Waterhouse
|
|
|
b)
|
Position/status
|
CEO, ViiV Healthcare and President, Global Health, GSK
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 January 2025 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.4950
|
471
|
|
|
|
£13.4950
|
531
|
|
|
|
£13.4950
|
130
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume
Price
|
1,132
£13.4950
|
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Tony Wood
|
|
b)
|
Position/status
|
Chief Scientific Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2025
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.4950
|
223
|
|
|
|
£13.4950
|
654
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
877
£13.4950
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Emma Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature of
the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 9 January 2025 on Ordinary Shares
held in the Company's Performance Share Plan subject to a 2-year
holding period
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.4950
|
8001.047
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
Aggregated volume
Price
|
N/A (single transaction)
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr Hal Barron
|
|
b)
|
Position/status
|
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
b)
|
Nature
of the transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 9 January 2025
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$32.1317
|
3445.486
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
James Ford
|
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
b)
|
Nature
of the transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 9 January 2025
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$32.1317
|
371.810
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Shobie Ramakrishnan
|
|
b)
|
Position/status
|
Chief Digital and Technology Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
b)
|
Nature
of the transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 9 January 2025
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$32.1317
|
183.525
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2025-01-14
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: January
15, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Dec 2024 to Jan 2025
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Jan 2024 to Jan 2025
